{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:30:51Z","timestamp":1791477051521,"version":"4.3.4"},"reference-count":57,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH","award":["F31 CA305954"],"award-info":[{"award-number":["F31 CA305954"]}]},{"name":"NIH","award":["P01 CA250972"],"award-info":[{"award-number":["P01 CA250972"]}]},{"name":"NIH","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}]},{"name":"NIH","award":["T32 CA009135"],"award-info":[{"award-number":["T32 CA009135"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,6,3]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radiopharmaceutical therapy (RPT) delivers radiation systemically, enabling the treatment of metastatic cancers. Beyond killing tumor cells, RPT can modulate the tumor immune microenvironment. With RPTs and immunotherapies already approved or in development for prostate cancer, many preclinical and clinical studies are evaluating their use in combination. However, due to the radiosensitivity of tumor-infiltrating lymphocytes, further studies are needed to determine the effects of RPT on these cells to better inform the sequence of immunotherapies that activate T cells when given with RPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      E.G7-OVA tumor-bearing mice received na\u00efve or activated OT-I CD8+T cells prior to or following the administration of RPT using\n                      <jats:sup>90<\/jats:sup>\n                      Y-NM600. Changes in tumor growth were monitored, and tumor-infiltrating lymphocytes were evaluated for phenotypic and functional markers. The murine prostate tumor model TRAMP-C1 was used to evaluate this approach using tumor antigen-specific vaccination with\n                      <jats:sup>90<\/jats:sup>\n                      Y-NM600.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Antitumor efficacy was improved if OT-I CD8+T cells were present and activated prior to\n                      <jats:sup>90<\/jats:sup>\n                      Y-NM600 administration than if the cells were delivered after RPT. Similarly, in vivo activation of adoptively transferred OT-I CD8+T cells, using ovalbumin (OVA)-specific vaccination, prior to RPT slowed tumor growth and increased the frequency of tumor-infiltrating OVA\n                      <jats:sub>257-264<\/jats:sub>\n                      -specific CD8+T cells with effector memory phenotype and effector molecule production. Blockade of type I interferon, but not the upstream inhibition of stimulator of interferon genes, abrogated tumor growth delay resulting from the combination treatment. Tumor antigen-specific vaccination prior to\n                      <jats:sup>90<\/jats:sup>\n                      Y-NM600 administration similarly improved antitumor outcomes in the TRAMP-C1 tumor model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study suggests that tumor-specific CD8+T cells need to be present and activated prior to RPT to enhance antitumor outcomes. This study highlights the importance of considering the effects of RPT on tumor-infiltrating CD8+T cells when combining other T-cell activating therapies with RPT, as they may similarly display sequence-dependent antitumor outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015261","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:50:40Z","timestamp":1781873440000},"page":"e015261","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5789-467X","authenticated-orcid":false,"given":"Daeun","family":"Shim","sequence":"first","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Mouton","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6849-3225","authenticated-orcid":false,"given":"Jena E","family":"Moseman","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansel","family":"Comas Rojas","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghwan","family":"Jeon","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malick B","family":"Idrissou","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier","family":"Hernandez","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamey P","family":"Weichert","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1471-6723","authenticated-orcid":false,"given":"Douglas G","family":"McNeel","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"2026061905503079000_14.6.e015261.1","unstructured":"McNeel D , Shim D . Data from: activation of tumor-specific cd8+ t cells prior to radiopharmaceutical therapy improves anti-tumor response. Gene Expression Omnibus; 2026. Available: https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE330657"},{"key":"2026061905503079000_14.6.e015261.2","doi-asserted-by":"crossref","first-page":"e1945","DOI":"10.1016\/S2214-109X(24)00355-3","article-title":"Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based study","volume":"12","author":"Zhu","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2026061905503079000_14.6.e015261.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02041-6"},{"key":"2026061905503079000_14.6.e015261.4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/pro6.1239","article-title":"Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy","volume":"8","author":"Varghese","year":"2024","journal-title":"Precis Radiat Oncol"},{"key":"2026061905503079000_14.6.e015261.5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.7150\/thno.79806","article-title":"Radiopharmaceuticals heat anti-tumor immunity","volume":"13","author":"Sun","year":"2023","journal-title":"Theranostics"},{"key":"2026061905503079000_14.6.e015261.6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005060","article-title":"Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors","volume":"10","author":"Potluri","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026061905503079000_14.6.e015261.7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008760","article-title":"Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors","volume":"12","author":"Muralidhar","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026061905503079000_14.6.e015261.8","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.trecan.2023.07.014","article-title":"Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors","volume":"9","author":"Pouget","year":"2023","journal-title":"Trends Cancer"},{"key":"2026061905503079000_14.6.e015261.9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.37549\/ARO-D-24-00039","article-title":"Clinical Evidence of Combining Radiopharmaceutical Therapy With Immune Checkpoint Inhibitors","volume":"14","author":"Idrissou","year":"2025","journal-title":"ARO"},{"key":"2026061905503079000_14.6.e015261.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217986"},{"key":"2026061905503079000_14.6.e015261.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19147","article-title":"Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects","volume":"9","author":"He","year":"2023","journal-title":"Heliyon"},{"key":"2026061905503079000_14.6.e015261.12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1399802","article-title":"Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future","volume":"15","author":"Lampe","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026061905503079000_14.6.e015261.13","doi-asserted-by":"crossref","first-page":"110091","DOI":"10.1016\/j.radonc.2024.110091","article-title":"The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer","volume":"192","author":"Saylor","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026061905503079000_14.6.e015261.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.246041"},{"key":"2026061905503079000_14.6.e015261.15","doi-asserted-by":"crossref","unstructured":"Liu J , Ren Y , Poku K , et al . 309 Combining radiopharmaceutical therapy with car t cells to overcome the heterogeneous immunosuppressive prostate tumor microenvironment. SITC 40th Annual Meeting (SITC 2025) Abstracts; November 2025 Available: https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0309","DOI":"10.1136\/jitc-2025-SITC2025.0309"},{"key":"2026061905503079000_14.6.e015261.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0063"},{"key":"2026061905503079000_14.6.e015261.17","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2326-6066.CIR-22-0306","article-title":"Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer","volume":"12","author":"Choudhury","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"2026061905503079000_14.6.e015261.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4476"},{"key":"2026061905503079000_14.6.e015261.19","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","article-title":"PRINCE: Phase I trial of 177 Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Sandhu","year":"2022","journal-title":"JCO"},{"key":"2026061905503079000_14.6.e015261.20","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026061905503079000_14.6.e015261.21","unstructured":"National Cancer Institute (NCI) . A phase i and randomized phase ii trial of radium-223 dichloride, m3814, &amp; avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC). Report no.: NCT04071236 . clinicaltrials.gov; 2026. Available: https:\/\/clinicaltrials.gov\/study\/NCT04071236 [accessed 26 Jan 2026]"},{"key":"2026061905503079000_14.6.e015261.22","unstructured":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group . Accessed 26 Jan 2026. Phase ii study of radionuclide 177lu-psma therapy versus 177lu-psma in combination with ipilimumab and nivolumab for men with metastaticcastration resistant prostate cancer (mCRPC). Report no.: NCT05150236 . clinicaltrials.gov; 2023.:CT05150236. Available: https:\/\/clinicaltrials.gov\/study\/NCT05150236 [accessed 26 Jan 2026]"},{"key":"2026061905503079000_14.6.e015261.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224808"},{"key":"2026061905503079000_14.6.e015261.24","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-019-0327-4","article-title":"90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin\u2019s Lymphoma","volume":"2","author":"Hernandez","year":"2019","journal-title":"Commun Biol"},{"key":"2026061905503079000_14.6.e015261.25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/HP.0000000000000789","article-title":"Murine-specific Internal Dosimetry for Preclinical Investigations of Imaging and Therapeutic Agents","volume":"114","author":"Bednarz","year":"2018","journal-title":"Health Phys"},{"key":"2026061905503079000_14.6.e015261.26","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/2326-6066.CIR-24-1191","article-title":"The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy","volume":"13","author":"Kerr","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"2026061905503079000_14.6.e015261.27","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0374"},{"key":"2026061905503079000_14.6.e015261.28","doi-asserted-by":"crossref","first-page":"115566","DOI":"10.1016\/j.celrep.2025.115566","article-title":"Pre-existing intratumoral stem-like CD8+ T cells drive radiotherapy-induced tumor immunity","volume":"44","author":"K\u00f6ksal","year":"2025","journal-title":"Cell Rep"},{"key":"2026061905503079000_14.6.e015261.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11906-2","article-title":"Tumor-reprogrammed resident T cells resist radiation to control tumors","volume":"10","author":"Arina","year":"2019","journal-title":"Nat Commun"},{"key":"2026061905503079000_14.6.e015261.30","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-0867-4","article-title":"XAF1 forms a positive feedback loop with IRF-1 to drive apoptotic stress response and suppress tumorigenesis","volume":"9","author":"Jeong","year":"2018","journal-title":"Cell Death Dis"},{"key":"2026061905503079000_14.6.e015261.31","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02582-24","article-title":"Interference without interferon: interferon-independent induction of interferon-stimulated genes and its role in cellular innate immunity","volume":"15","author":"Swaraj","year":"2024","journal-title":"MBio"},{"key":"2026061905503079000_14.6.e015261.32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2054758","article-title":"Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon \u00df-mediated suppression of immune checkpoint receptor expression","volume":"11","author":"Jeon","year":"2022","journal-title":"Oncoimmunology"},{"key":"2026061905503079000_14.6.e015261.33","unstructured":"Inc R . Discovery platform & data hub for scientists | rosalind\u00ae. 2025. Available: https:\/\/www.rosalind.bio [Accessed 28 Dec 2025]."},{"key":"2026061905503079000_14.6.e015261.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1363-9"},{"key":"2026061905503079000_14.6.e015261.35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228877","article-title":"The Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer","volume":"21","author":"Storozynsky","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026061905503079000_14.6.e015261.36","first-page":"2661","article-title":"Effects of iodine-131 radiotherapy on Th17\/Tc17 and Treg\/Th17 cells of patients with differentiated thyroid carcinoma","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"2026061905503079000_14.6.e015261.37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.667658","article-title":"Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer","volume":"11","author":"Creemers","year":"2021","journal-title":"Front Oncol"},{"key":"2026061905503079000_14.6.e015261.38","doi-asserted-by":"crossref","unstructured":"Muralidhar A , Law K , Fan Z , et al . 674 multi-omic single-cell assessment of castration-resistant prostate cancer patients receiving 17 7lu-psma-617 and pembrolizumab shows timing of radioligand therapy alters immune response. SITC 40th Annual Meeting (SITC 2025) Abstracts; November 2025 Available: https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0674","DOI":"10.1136\/jitc-2025-SITC2025.0674"},{"key":"2026061905503079000_14.6.e015261.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019"},{"key":"2026061905503079000_14.6.e015261.40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1563387","article-title":"Immunomodulatory effects of alpha vs beta radiopharmaceutical therapy in murine prostate cancer","volume":"16","author":"Ferreira","year":"2025","journal-title":"Front Immunol"},{"key":"2026061905503079000_14.6.e015261.41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk0642","article-title":"Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade","volume":"16","author":"Jagodinsky","year":"2024","journal-title":"Sci Transl Med"},{"key":"2026061905503079000_14.6.e015261.42","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"2026061905503079000_14.6.e015261.43","doi-asserted-by":"publisher","DOI":"10.7150\/thno.54881"},{"key":"2026061905503079000_14.6.e015261.44","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1078-0432.CCR-23-3206","article-title":"Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites","volume":"30","author":"Hou","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026061905503079000_14.6.e015261.45","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Sig Transduct Target Ther"},{"key":"2026061905503079000_14.6.e015261.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00340-5"},{"key":"2026061905503079000_14.6.e015261.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09370-8"},{"key":"2026061905503079000_14.6.e015261.48","doi-asserted-by":"crossref","first-page":"111647","DOI":"10.1016\/j.celrep.2022.111647","article-title":"Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy","volume":"41","author":"Chen","year":"2022","journal-title":"Cell Rep"},{"key":"2026061905503079000_14.6.e015261.49","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ijrobp.2025.04.011","article-title":"Stimulator of Interferon Genes Agonist Synergistically Amplifies Programmed Cell Death Protein-1 Blockade and Radiation-Induced Systemic Antitumor Responses via Tumor Microenvironment Enrichment","volume":"123","author":"Zheng","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026061905503079000_14.6.e015261.50","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1201500","article-title":"A review on lymphocyte radiosensitivity and its impact on radiotherapy","volume":"13","author":"Paganetti","year":"2023","journal-title":"Front Oncol"},{"key":"2026061905503079000_14.6.e015261.51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400434"},{"key":"2026061905503079000_14.6.e015261.52","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262977"},{"key":"2026061905503079000_14.6.e015261.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026061905503079000_14.6.e015261.54","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1383000","article-title":"Harnessing the cGAS-STING pathway to potentiate radiation therapy: current approaches and future directions","volume":"15","author":"Colangelo","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026061905503079000_14.6.e015261.55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.622509","article-title":"Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy","volume":"11","author":"Jiang","year":"2020","journal-title":"Front Immunol"},{"key":"2026061905503079000_14.6.e015261.56","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1158\/0008-5472.CAN-23-3257","article-title":"A Prime-Boost Vaccination Approach Induces Lung Resident Memory CD8+ T Cells Derived from Central Memory T Cells That Prevent Tumor Lung Metastasis","volume":"84","author":"Xu","year":"2024","journal-title":"Cancer Res"},{"key":"2026061905503079000_14.6.e015261.57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1204363","article-title":"Strategies to reinvigorate exhausted CD8+ T cells in tumor microenvironment","volume":"14","author":"Guan","year":"2023","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:50:47Z","timestamp":1781873447000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,19]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/jitc-2026-015261"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015261","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}